Literature DB >> 6840861

Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus.

J W LeDuc, S M Lemon, C M Keenan, R R Graham, R H Marchwicki, L N Binn.   

Abstract

Epidemiological studies have demonstrated the susceptibility of the owl monkey (Aotus trivirgatus) to hepatitis A virus, but have not shown an association between infection and histopathological or chemical evidence of liver disease. Therefore, 12 seronegative, colony-bred monkeys were inoculated intravenously with a fecal suspension containing either PA33 strain hepatitis A virus (a strain recovered from a naturally infected Aotus sp.) or HM-175 virus (recovered from a human). Viral antigen was detected by radioimmunoassay in the feces of six monkeys 6 to 17 days after inoculation with PA33 virus, and by 9 to 21 days serum aminotransferase activities were significantly elevated in each. Antibody to the virus developed in each monkey by 28 days after inoculation. Similar findings were noted in five of six monkeys inoculated with HM-175 virus, although the incubation period preceding aminotransferase elevations was somewhat longer (25 to 39 days). Liver biopsies obtained from the 11 infected monkeys demonstrated mild to moderate portal inflammation, as well as random areas of focal necrosis and inflammation extending outward from the portal region. These data confirm the susceptibility of Aotus sp. to hepatitis A virus and indicate that the infection of this primate provides a useful animal model of human hepatitis A.

Entities:  

Mesh:

Year:  1983        PMID: 6840861      PMCID: PMC264921          DOI: 10.1128/iai.40.2.766-772.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Propagation of human hepatitis A virus in cell culture in vitro.

Authors:  P J Provost; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1979-02

2.  Suitability of the rufiventer marmoset as a host animal for human hepatitis A virus.

Authors:  P J Provost; V M Villarejos; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1977-07

Review 3.  Hepatitis A virus: identification, characterization, and epidemiologic investigations.

Authors:  J L Dienstag
Journal:  Prog Liver Dis       Date:  1979

4.  New herpesviruses from South American monkeys. Preliminary report.

Authors:  L V Melendez; M D Daniel; H H Barahona; C E Fraser; R D Hunt; F G Garcia
Journal:  Lab Anim Sci       Date:  1971-12

Review 5.  Hepatitis in primates.

Authors:  F Deinhardt
Journal:  Adv Virus Res       Date:  1976       Impact factor: 9.937

6.  Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies.

Authors:  L H Schmidt
Journal:  Trans R Soc Trop Med Hyg       Date:  1973       Impact factor: 2.184

7.  Experimental infection of chimpanzees with hepatitis A virus.

Authors:  J L Dienstag; S M Feinstone; R H Purcell; J H Hoofnagle; L F Barker; W T London; H Popper; J M Peterson; A Z Kapikian
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

8.  The pathology of hepatitis A in man.

Authors:  M R Teixeira; I V Weller; A Murray; M Bamber; H C Thomas; S Sherlock; P J Scheuer
Journal:  Liver       Date:  1982-03

9.  Susceptibility of monkeys to human hepatitis A virus.

Authors:  J S Mao; Y Y Go; H Y Huang; P H Yu; B Z Huang; Z S Ding; N L Chen; J H Yu; R Y Xie
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

10.  Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage.

Authors:  R J Daemer; S M Feinstone; I D Gust; R H Purcell
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

  10 in total
  15 in total

1.  High prevalence of antibodies against hepatitis A virus among captive nonhuman primates.

Authors:  Pattaratida Sa-nguanmoo; Nutchanart Thawornsuk; Pornpimol Rianthavorn; Angkana Sommanustweechai; Parntep Ratanakorn; Yong Poovorawan
Journal:  Primates       Date:  2009-10-10       Impact factor: 2.163

2.  Combined immunoaffinity cDNA-RNA hybridization assay for detection of hepatitis A virus in clinical specimens.

Authors:  R W Jansen; J E Newbold; S M Lemon
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

3.  Comparison and characterization of immunoglobulin G subclasses among primate species.

Authors:  M H Shearer; R D Dark; J Chodosh; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures.

Authors:  L N Binn; S M Lemon; R H Marchwicki; R R Redfield; N L Gates; W H Bancroft
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

5.  Antigenic relatedness of two strains of hepatitis A virus determined by cross-neutralization.

Authors:  S M Lemon; L N Binn
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

6.  Growth of hepatitis A virus in a mouse liver cell line.

Authors:  Dino A Feigelstock; Peter Thompson; Gerardo G Kaplan
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Characterization of a simian hepatitis A virus (HAV): antigenic and genetic comparison with human HAV.

Authors:  E A Brown; R W Jansen; S M Lemon
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Pathology of hepatitis A infection in the owl monkey (Aotus trivirgatus).

Authors:  C M Keenan; S M Lemon; J W LeDuc; G A McNamee; L N Binn
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

9.  Utilization of chimeras between human (HM-175) and simian (AGM-27) strains of hepatitis A virus to study the molecular basis of virulence.

Authors:  G Raychaudhuri; S Govindarajan; M Shapiro; R H Purcell; S U Emerson
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Hypertrophic cardiomyopathy in owl monkeys (Aotus spp.).

Authors:  Grant G Knowlen; Richard E Weller; Ruby L Perry; Janet F Baer; Alfonso S Gozalo
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.